Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01897571 · ClinicalTrials.gov registry record · Phase 1
Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL
A Phase 1 study, sponsored by Epizyme.
- Completed
- Registry status
- Phase 1
- Development phase
- 400
- Enrollment target
NCT01897571 is a Phase 1 study that has completed, run by Epizyme. The registered enrollment target is 400 participants.
The verdict
NCT01897571, a Phase 1 study, has completed, sponsored by Epizyme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 400 participants
- Enrollment target
Study Summary
This is an open-label, multicenter, Phase 1/2 study of tazemetostat as a single agent in subjects with advanced solid tumors or with B-cell lymphomas and tazemetostat in combination with prednisolone in subjects with diffuse large B-cell lymphoma (DLBCL).
Interventions
- DRUG Prednisolone
- DRUG Tazemetostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2013-06-13 |
| Est. Completion | 2021-11-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01897571
The ClinicalTrials.gov registry entry for NCT01897571 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Epizyme, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Prednisolone is the first listed.
NCT01897571 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01897571 about?
NCT01897571 is a clinical study titled "Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL". This is an open-label, multicenter, Phase 1/2 study of tazemetostat as a single agent in subjects with advanced solid tumors or with B-cell lymphomas and tazemetostat in combination with prednisolone in subjects with diffuse large B-cell lymphoma (DLBCL).
What is the current status of trial NCT01897571?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 400 participants. The study started on 2013-06-13. Estimated completion is 2021-11-02.
What interventions are being tested in trial NCT01897571?
The interventions under investigation include: Prednisolone (DRUG), Tazemetostat (DRUG).
Who is sponsoring clinical trial NCT01897571?
This trial is sponsored by Epizyme, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.